The DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Abstract
BACKGROUND: Among breast cancer patients, tamoxifen use is associated with reduced risk of disease relapse and death, but it is often difficult for women to sustain therapy during the 5 years required to obtain maximum benefit. OBJECTIVES: We sought to examine the influence of patient-centered care activities on ongoing tamoxifen use 4 years after initiation, we examined key components of patient-centered care and rates of ongoing tamoxifen. METHODS: Using a prospective cohort study that included observational data from the National Initiative for Cancer Care Quality (NICCQ), we studied 881 patients with stage I-III breast cancer who were registered with an initial diagnosis in 1998 by an American College of Surgeons-approved hospital cancer registry in 1 of 5 metropolitan areas, who initiated tamoxifen treatment. A patient survey and medical record abstraction were used as measurements. RESULTS: Among women who initiated tamoxifen, 79% were still taking it 4 years later. Other than older age and the severity of side effects, other demographic, clinical and cancer characteristics, and treatments did not predict ongoing tamoxifen use. In contrast, after adjusting for these factors, the proportion of patients with ongoing tamoxifen use was lower for patients reporting less support than needed (82% vs. 69%, P = 0.0051), less than wanted role in decision-making (80% vs. 70%, P = 0.0486), decision-making about tamoxifen without doctor input (79% vs. 64%, P = 0.0182), and for patients who weren't told about side effects in advance (82% vs. 72%, P = 0.0016). CONCLUSIONS: Although age and the severity of side-effects remain important, patient-centered care was a primary mediator of patient adherence to ongoing cancer treatment with tamoxifen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [16]
In the citing paper
“There is also evidence that survivors who reported (1) lack of understandable information about treatment, (2) not being told about side effects in advance, (3) having limited opportunity to ask questions at the time of diagnosis, and (4) never having been asked about the difficulties of taking adjuvant hormonal therapy, exhibited lower rates of adherence to hormonal treatment.16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [16]
In the citing paper
“Social support has also been associated with higher adherence in a meta-analysis with various medical conditions46 and in several adjuvant hormonal therapy studies with breast cancer survivors.16, 17, 47”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [16]
Citations
Cites
Adherence to Long-Term Therapies: Evidence for Action
Geest, S. D., & Sabate, E. J. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,310
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Crossing the Quality Chasm: A New Health System for the 21st Century
Bloom, B. S. (2002) · JAMA · doi:10.1001/jama.287.5.646-a · Cited by 3,733
The impact of patient-centered care on outcomes.
Stewart, M., Brown, J. B., DONNER, A. P., McWhinney, I. R., Oates, J., Weston, W. W., & Jordan, J. (2000) · PubMed · Cited by 2,508
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease
Kaplan, S. H., Greenfield, S., & Ware, J. E. (1989) · Medical Care · doi:10.1097/00005650-198903001-00010 · Cited by 2,043
Expanding Patient Involvement in Care
Greenfield, S., Kaplan, S. H., & Ware, J. E. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-4-520 · Cited by 1,459
Recall bias in epidemiologic studies
Coughlin, S. S. (1990) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(90)90060-3 · Cited by 1,381
Effectiveness of Interventions to Improve Patient Compliance
ROTER, D. L., Hall, J. A., Merisca, R., Nordstrom, B. L., Cretin, D., & Svarstad, B. L. (1998) · Medical Care · doi:10.1097/00005650-199808000-00004 · Cited by 998
Cited by
Sorted by citations
Doyle, C., Lennox, L., & Bell, D. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001570 · Cited by 2,666
Patient-Centered Care and Outcomes: A Systematic Review of the Literature
Rathert, C., Wyrwich, M. D., & Boren, S. A. (2013) · Medical Care Research and Review · doi:10.1177/1077558712465774 · Cited by 1,087
“In their study of breast cancer survivors, Kahn et al. (2007) found that women who received the right amount of support from their providers were more likely to continue their tamoxifen use 4 years after starting it.”
BackgroundInfluentialExamining the Role of Patient Experience Surveys in Measuring Health Care Quality
Price, R. A., Elliott, M. N., Zaslavsky, A. M., Hays, R. D., Lehrman, W. G., Rybowski, L., Edgman‐Levitan, S., & Cleary, P. D. (2014) · Medical Care Research and Review · doi:10.1177/1077558714541480 · Cited by 861
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
“Patients who experience treatmentrelated adverse effects are more likely to discontinue adjuvant endocrine therapy, particularly during the first years.(100,101) Adverse effects were the most common reason for discontinuation, particularly during the first year according to one study.”
BackgroundResultSelf-citationMurphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Metadata
- Authors
- Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M.
- Affiliations
- RAND Corporation (US)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- Corresponding author
- Kahn, Katherine L.
- Adams, John L.
- Venue
- Medical Care
- Published
- 2007-05
- Volume
- 45
- Issue
- 5
- Pages
- 431-439
- ISSN
- 0025-7079 (ISSN-L)
- OpenAlex
- W1979710912
- Cited by
- 245
- References
- 44
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 13 · 2019: 10 · 2018: 17 · 2017: 18 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 29 · 2012: 14
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Medical Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- breast cancer, tamoxifen, patient-centered care, medication adherence, patient support, shared decision-making, treatment side effects
- MeSH terms
- Adult, Aged, Aged, 80 and over, Breast Neoplasms, Female, Humans, Medical Audit, Middle Aged, Neoplasm Staging, Patient Compliance, Patient Participation, Prospective Studies, Tamoxifen, Time Factors, United States, Cohort Studies, Patient-Centered Care, Health Care Surveys
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
